Additionally, tumor proteins such as KRAS, CDKN2A, and TP53 often indicate poor prognosis.[37] Establishing a comprehensive molecular profile can provide more objective recurrence risk stratification and better assessment of transplantation prognosis. This evidence concerns the gene KRAS and neoplasm.